Loading…
Loading…
Australian Clinical Labs (ASX:ACL), a pathology provider, is held by value managers who see long-term potential despite sector headwinds. In August 2026, Investors Mutual described ACL as a core small-cap healthcare holding, noting it continues to perform despite government funding cuts to major tests and above-inflation wage increases. Allan Gray highlighted ACL as an example of a company with significant operating leverage in a sector that has been out of favour, and Investors Mutual noted a 9% fall as healthcare stocks were sold off. Australian Clinical Labs operates in the Healthcare sector within the Healthcare Providers and Services industry, and Thesis Tracker has captured 5 comments from 4 fund managers, including Investors Mutual and Allan Gray. Founded in 2015 and headquartered in Clayton, Melbourne, ACL provides pathology services through collection centres and laboratories across Australia, serving doctors, hospitals and patients.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Wilson Asset Management, Allan Gray, Investors Mutual Limited and First Samuel have invested in Australian Clinical Labs Ltd (ASX:ACL).
Investors Mutual and Allan Gray highlight ACL's operating leverage, ability to outperform larger peers on margins and long-term potential in an out-of-favour sector.
Investors Mutual notes government funding cuts for major tests, above-inflation wage increases and weak sentiment toward healthcare stocks.
Australian Clinical Labs Ltd. is a provider of pathology and clinical laboratory services across Australia. Founded in 2015 and headquartered in Clayton, Australia, the company operates exclusively within the pathology segment. It delivers essential diagnostic testing services, serving the healthcare sector through its nationwide laboratory network. The firm focuses on professional pathology operations to support patient outcomes and clinical decision-making. As an Australian-based entity, Clinical Labs maintains a centralized service model to facilitate efficient diagnostic workflows for healthcare providers and patients.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.